

Alphamab Oncology (9966.HK) 2023 Annual Results Presentation

March 2024

Disclaimer



This presentation has been prepared by Alphamab Oncology (the "Company") solely for use at the presentation held in 2024.

The information contained in this presentation has not been independently verified. No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information contained herein. The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. Neither the Company nor any of its affiliates, advisers or representatives accepts any liability whatsoever for any actual or consequential loss or damages howsoever arising from the provision or use of any information contained in this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such alternations, modifications or changes.

This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as "expects," "plan," "will," "estimates," "projects," "intends," or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward-looking statements contained in this presentation to reflect future events or circumstances. Accordingly, you should not place undue reliance on any forward-looking information.

This presentation is highly confidential, is being presented solely for your information and for your use and may not be copied, reproduced or redistributed to any other person in any manner without the Company's prior written consent. Unauthorized copying, reproduction or redistribution of this presentation could be limited or prohibited by the securities laws of various jurisdictions.

This presentation is for information purposes only and does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, any of its holding companies, or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the business, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

No securities of the Company may be offered, sold or transferred within the United States or to, or for the account or benefit of U.S. persons, without registration with the United States Securities and Exchange Commission, except as pursuant to an exemption from, or in a transaction not subject to, such registration requirements. The Company has not registered and does not intend to register any securities of the Company under the U.S. Securities Act of 1933, as amended. There will be no public offering of any securities by the Company in the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the Offering for subscription of such shares has been formally approved by The Stock Exchange of Hong Kong Limited in accordance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) and duly registered by the Registrar of Companies in Hong Kong. The securities referred to herein have not been and will not be registered under the applicable securities laws of the People's Republic of China (the "PRC"), and may not be offered or sold within the PRC or to any national, resident or citizen of the PRC.

By attending this presentation, participants agree not to remove this presentation, or any materials provided in connection herewith, from the conference room or online platform where such presentation or materials are provided. Participants further agree not to photograph, copy or otherwise reproduce these materials during the presentation or while in the conference room. Participants must return this presentation and all other materials provided in connection herewith to the Company at the completion of the presentation. By attending this presentation, you are agreeing to be bound by the restrictions and other limitations set forth herein. Any failure to comply with these limitations may constitute a violation of law and may lead to legal or regulatory action.








01


Financial Overview in 2023

Overview of Key Financial Data

康宁杰瑞

(RMB)





Consolidated Statement of Comprehensive Income



	For the year ended December 31	
(RMB'000)	2023	2022
Revenue	218,774	166,845
Cost of Sales	(55,237)	(44,207)
Gross profit	163,537	122,638
Other income	91,817	57,782
Other gains and losses	33,094	63,073
R&D expenses	(407,524)	(468,238)
Administrative expenses	(79,338)	(86,771)
Finance costs	(12,179)	(14,206)
Loss before taxation	(210,593)	(325,722)
Income tax expense	-	-
Loss for the period	(210,593)	(325,722)




02

Business Review

/ ≰

 $| \geq$

Major Progress of Core Business Operations from January 2023 to March 2024



Note:1. JITC: Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer; EJC: European Journal of Cancer, the official journal of the European Organization for Research and Treatment of Cancer and the European Society of Breast Cancer Specialists 2. MSI-H: metastatic advanced microsatellite instability-high; 8 dMMR: mismatch-repair deficiency



03

Outlook for 2024

Key Milestones and Catalyst in 2024



Key Clinical Trials Progress

- KN046+chemo, 1L sq-NSCLC: Continue the data follow-up till the final OS analysis
- KN046+chemo, 1L PDAC: Continue the data follow-up till the final OS analysis
- KN046+Axitinib: Partial clinical data readout
- JSKN003, monotherapy: To advance the phase III clinical trial enrollment and initiate 2 pivotal trials
- JSKN033: Complete the dose escalation stage of phase I clinical trial in Australia

Clinical Trial Data Plan to Release

AACR (April 2024)



1. JSKN003: phase I clinical trial in Australia, HER2 expression solid tumor

ASCO (Plan to release, June 2024)

2024 ASCO ANNUAL MEETING

1. JSKN003: partial data of phase I clinical trial in Australia and phase I/II clinical trial in China, HER2 expression solid tumor

ESMO (Plan to release, October, 2024)

- 1. KN046+Axitinib: phase II clinical trial, NSCLC
- SABCS (Plan to release, December 2024)



1. JSKN003: HER2 expression BC


New Candidates Progress and Others

• JSKN016: IND approved, and advance phase I clinical trial

• Drive the upgrading of ADC drug research and development and production process












KN046 KN026 Dual blockade of PD-L1 JSKN003 and CTLA-4 **Dual blockade of HER2** KN035 domain II and IV HER2 bispecific ADC - PD-(L)1 refractory solid tumor - PD-(L)1 Inadequate - Positioning the first line and response








Subcutaneous PD-L1 mAb





Mechanism of Action



Highlights

Targeted drug delivery

- Engineered to enable the anti-PD-L1 sdAb to dominate drug distribution
- Targeted drug delivery to enrich KN046 in tumorrelated micro-environment and limit exposure to non-tumor tissues

Different CTLA-4 binding epitope

- Our anti-CTLA-4 sdAb mainly binds outside the interface and blocks the CTLA-4/B7 with steric hindrance
- Lead to a potentially improved safety profile
- Preservation of Fc-mediated effector functions
 - Preserves the full Fc functions for Treg Depletion
- Strong Scientific base to support targeting CTLA-4 and PD-L1 with Bispecifics




Indication	Mono/ Combo	IND	Proof of concept	Pivotal	NDA
1L sq NSCLC	+chemo				,
1L PDAC	+chemo				,
1L NSCLC	+axitinib			,	
PD-(L)1 refractory NSCLC	+axitinib				




Indication & Strac	KN046(Over 1,200 patients have been enrolled in clinical studies)				
Efficacy Safety	sq-NSCLC 1L (n=87)	PDAC 1L (n=53)	HCC 1L (n=55)	TNBC 1L (n=27)	ESCC 1L (n=15)
Mono/Combo	+chemo	+chemo	+lenvatinib	+chemo	+chemo
OS	26.6 months	12 months		30.92 months (immature)	
mPFS	5.7 months	6 months	11 months	7.33 months	
ORR	50%	47.9%	45.5%	44%	58.3%
DCR	80.6%	93.5%	89.1%	96%	91.6%
TRAE≥Grade3	34.5%(TEAE)	27.6%	47.3%	66.7%	29.4% (related to KN046)

KN046-301 (phase III) 1L NSCLC (ENREACH-LUNG-01)-Trial Design







Stratification

- Tumor Staging
- Location of the primary lesion
- ECOG score, etc.

Primary Endpoint

• OS

Secondary Endpoint

- ORR
- PFS



KN046-209 without chemotherapy: Inclusion criteria overview

- ✓ NSCLC patients in stage IIIB-IV
- ✓ PD-(L)1+ (TPS≥1%) (cohort A)
- ✓ No driver gene mutations

Cohort A: For patients with treatment-naïve locally advanced (cannot be surgically removed and radical chemoradiotherapy)
 or metastatic PD-L1 positive NSCLC

✓ Cohort B: For NSCLC patients who progressed after prior PD-(L)1 inhibitor treatment

KN046-209(phase II) Cohort A 1L NSCLC (2023 ESMO)



Trial Design: 38 subjects with 1L NSCLC, systemic treatment-naïve and PD-L1 positive(TPS≥1) were enrolled. Among them, 86.8% of patients were at stage IV and 94.7% of patients had an ECOG PS=1. 26.3% of patients had 50% or higher PD-L1 expression, 65.8% of patients had 1%~49% PD-L1 expression and 5.3% had less than 1% PD-L1 expression. Squamous and non-squamous NSCLC patients accounted for 42.1% and 52.6% respectively.



Efficacy: Among 29 evaluable patients, the ORR was 58.6%, the DCR was 96.6%, the mPFS was 8.35 months(not mature)¹. The mOS was not reached yet. The ORR in patients with high PD-L1 expression was 83.3%. And the mPFS in non-squamous NSCLC patients was 9.20 months(not mature).

Comparable trials	KN046-209			SUNRISE
Drug	KN046+axitinib	Camrelizumab+famitinib	Toripalimab+surufatinib ²	Sintilimab+anlotinib ³
Line	1L	1L	1L	1L
n	29	41 (PD-L1 high expression account for 48.8%)	23 (PD-L1 high expression account for 43.5%)	40
ORR	58.6% (PD-L1 high expression: 83.3%)	53.7% (PD-L1 high expression: 60.0%)	57.1% (PD-L1 high expression: 66.7%)	50.0% (regardless of the PD-L1 expression)
mPFS	8.35 months (not mature)	16.6 months	9.6 months	10.8 months
OS rate		24-month: 76.8%	—	—

Safety: It has a good safety profile. Among 38 patients, the incidence of KN046-related TRAEs at grade 3 or higher levels was 23.75. The most frequent TRAEs include AST increased(7.9%), ALT increased(5.3%) and diarrhoea (5.3%).


Note: 1. KN046-209 is ongoing currently and the date cut-off date is August 8, 2023. The median follow-up was 4.17 months. 2. The dose regimen of Surufatinib is 250mg, one a day. The AE incidence at grade 3 or higher levels was 73.9%. 3. The incidence of TRAE at grade 3 or 4 levels was 11.6%.



KN046

Dual blockade of PD-L1 and CTLA-4


- PD-(L)1 refractory solid tumor
- PD-(L)1 Inadequate response



KN026

Dual blockade of HER2 domain II and IV


- Solid tumor with high HER2 expression
- Positioning the first line and perioperative period



JSKN003

HER2 bispecific ADC

- Highly expressed tumor that do not fully respond to anti-HER2 therapy
- Solid tumor with low HER2 expression
- In combination with products of other mechanisms



KN035


Subcutaneous PD-L1 mAb

- The first PD-L1mAb
- used for subcutaneous










KN026 Major Clinical Trial: HER2 Positive Solid Tumor



- In August 2021, we reached collaboration with CSPC related to breast cancer and GC/GEJ of KN026 in Chinese mainland, involving upfront payment of RMB150million and milestone payment of RMB850million and a double-digit sales commission
- CSPC is responsible for the clinical development and registration application under the joint development committee and pay the cost



Indication Efficiency	KN026 (Over 300 patients have been enrolled in clinical studies)				
Efficacy &	HER2+ BC 1L (n=57)	HER2+ BC NAT (n=30)	HER2+ GC 1L (n=39)	HER2+ GC ≥2L (n=39)	HER2+ CRC ≥3L (n=15)
Mono/Combo	+chemo	+chemo	+KN046	mono	+KN046
OS(months)	78.5% (30-months rate)			16.3	
mPFS(months)	27.7 (immature)		10.9	8.3	12.2
ORR	76.4%	56.7% (tpCR)	71.8%	56.0%	53.3%
DCR	100%	100%	92.6%	76.0%	93.3%
≥Grade3 AE	TEAE: 43.9% (related to KN026)	TEAE: 53.3%	TRAE: 16.1%	TRAE: 11.1%	7.7% increase in bilirubin 7.7% increase in AST

KN026-201 (Phase II) 1L HER2+BC (2023 SABCS)

圓



Trial design: 57 patients with HER2+ recurrent or metastatic BC were enrolled. Among them, 91.2% of patients were stage IV.

<u>Efficacy:</u> Among 55 evaluable patients, the confirmed ORR was 76.4%. The mPFS was 27.7 months. The mOS was not mature,
 and the 12-month, 24-month, 30-month OS rates were 93%, 84.1% and 78.5%, respectively.

<u>Comparable</u> <u>trials</u>	KN026-201 ¹	CLEOPATRA		PUFFIN (China)	PHILA
Drug	KN026+docetaxel ¹	Trastuzumab+Pertuzumab+docetaxel vs Trastuzumab+docetaxel ²		Trastuzumab+Pertuzumab+ docetaxel ³	Pyrotinib+Tratuzu mab+nab- paclitaxel ⁴
Line	1L	1L (8.4% of patients with IHC1+/ IHC2+)		1L	1L
N	57	402	406	122	297
ORR	76.4%	80.2%	69.3%	79.0%	82.8%
mPFS	27.7 (not mature)	18.5 months	12.4 months	16.5 months	24.3 months
24-month OS rate	84.1%	80% (57.1 months)	70% (40.8 months)	79.5%	-
	L				

<u>Safety:</u> Among 57 patients, the incidence rate of TEAE at grade 3 or higher levels was 63.2%. The incidence of TRAE related to KN026 was 43.9%, including neutrophil count decreased(24.6%), white blood cell count decreased (12.3%), etc.

Note: 1. The data cut-off date is September 15, 2023. **2.** In HPT and HT groups, the incidence of diarrhea at grade \geq 3 were 7.9% and 5.0%, respectively. The incidence of neutrophil count decreased at grade 3 or higher levels were 48.9% and 45.8%, respectively. The incidence of febrile neutropenia decreased t grade 3 or higher levels were 13.8% and 7.6%, respectively. In addition, the incidence of left ventricular ejection fraction decreased were 7.8% and 8.6%, respectively and the incidence of heart failure were both 2%. **3.** The incidence of AE at grade 3 or higher levels was 89.9%, among which diarrhea at grade 3 or higher levels was **46.5%**.

KN026-208 (Phase II) Neoadjuvant HER2+BC (2023 ESMO)



<u>Trial design:</u> 30 patients with HER2+ early or locally advanced BC and without any systemic treatment were enrolled. 86.7% of patients were with biopsy-confirmed lymph node metastases. 53.3% of patients were stage II and 46.7% of patients were stage III.

Efficacy: Among all patientst, the pCR rate was 56.7%, the bpCR rate was 60.0%. The ORR was 90.0%, and the confirmed ORR was 86.7%.


Comparable <u>trials</u>	KN026-208 ¹	Neosphere (phase II)		PEONY (Asia Pacific)	PHEDRA	
drug	KN026+docetaxel	Trastuzumab+Pertuzumab+docetaxel vs Trastuzumab+docetaxel		Trastuzumab+Pertuzu mab+docetaxel ²	Pyrotinib+Tratuzum ab+docetaxel ³	
n	30	107	107	219	178(lymph node metastases:70%)	
ORR	90.0%	-	-	88.6%	91.6%	
pCR	bpCR: 60.0% tpCR: 56.7%	bpCR: 45.8% tpCR: 39.3%	bpCR: 29.0% tpCR: 21.5%	tpCR: 39.3%	bpCR: 43.8% tpCR: 41.0%	
others	AE ≥ grade 3: 53.3%	5-year PFS rate: 86%	5-year PFS rate: 81%	AE ≥ grade 3: 70.6%	AE ≥ grade 3: 71% ²	

Safety: Among all 30 patients, the incidence of TEAE at grade 3 or higher levels was 53.3%, including neutrophil count decreased (50.0%), white blood cell count decreased (40.0%) and lymphocyte count decreased (10.0%). The incidence rate of SAE at grade 3 or higher levels was 6.7%. SAE related to KN026 occurred in only one patient.

Note: 1. The data cut-off date is November 21, 2022. **2.** According to the Pertuzumab instructions, the incidence of diarrhea at grade 3 to 4 levels of the Pertuzumab plus trastuzumab was 8.9%, and the incidence of all levels diarrhoea was 67.9%. **3.** The incidence of cardiotoxicity such as trastuzumab was 7%~8%, while the adverse reactions in the pyrotinib combination group were mainly diarrhea. The incidence of diarrhea at grade 3 or higher levels was **40%**.

KN026-203(Phase II): KN046+KN026, ≥3L HER2+ Solid Tumor (2023 ASCO)






Enrolled 26 patients, including 15 CRC patients, 5 NSCLC patients, 4 gallbladder cancer patients, 1 renal pelvis cancer patient and 1 pancreatic cancer patient. 92.3% of patients including all CRC patients had received two or more lines of prior treatment

- Efficacy: The confirmed ORR was 53.8%, DCR was 88.4%, 12-month PFS rate was 80.4%, Out of 15 evaluable CRC patients, the ORR was 53.3%, DCR was 93.3%, the mPFS was 12.2 months and the 12-month OS rate was 80.0%
 - <u>Safety:</u> 34.6% of patients had experienced at least one time ≥ grade 3 TRAEs, the most common TRAEs were infusion related reaction(38.5%), diarrhea(19.2%), anemia, AST/ALT increased, etc.




KN046 **Dual blockade of PD-L1** JSKN003 and CTLA-4 **Dual blockade of HER2** KN035 domain II and IV HER2 bispecific ADC - PD-(L)1 refractory solid Subcutaneous PD-L1 mAb - Highly expressed tumor that do not fully respond to anti-HER2 therapy Positioning the first line and - Solid tumor with low HER2 expression - In combination with products of other H01046 PD-01 E CTL54 mechanisms HER2是体 体积项目委员 HER2是体 体积或V表信

JSKN003: Anti-HER2 Bispecific ADC



Phase I: Dose Escalation Stage- accelerated titration BOIN design

Phase II: Expansion Stage at RDE³



Note: 1. A total of 9 doses, the starting dose is 1.0mg/kg

2. If the dose increases to 10.5mg/kg, it still does not reach MTD. The SMC decides whether to continue the dose increase

3. RDE: The recommended dose of cohort extension is selected by SMC according to Phase Ia data. Different cohort/tumor species can choose different RDE for extension

Comparison of JSKN003-101 and DS-8201 in Efficacy and Safety




	JSKN003-101(Australia)n=32¹	DS-8201 Phase I n=24 ²
ECOG score	ECOG≥1 53.1%	ECOG≥1 41.7%
Tumor type and proportion ³	BC 46.9%、GC 3.1%、OC 15.6%、 UC 12.5%、 EC 6.3%、LC 6.3%、 other 9.4%	BC 67.0%、GC 33.0%
Tumor metastasis proportion	90.6%	100.0%
Proportion of HER2 status	IHC 3+ 21.9%、 IHC 2+ 50.0%、 IHC 1+/0 28.1%	IHC 3+ 62.5%、IHC 2+ 16.7%、 IHC 1+/0 20.8%
Number of treatment lines	≥3 line 62.5%	≥3 line 79.2%
The proportion of frontline treated with trastuzul or T-DM1	21.9%	75.0%
Grade ≥3 TRAE incidence rate	6.3%	75.0%
SAE	none	12.5%
Hematological toxicity incidence rate	3.1%	Decreased platelet count 33%、Decreased neutrophil count 25%、Decreased white blood cell count 21%、Decreased lymphocyte count 13%、Febrile neutropenia 4%
Overall ORR、DCR	46.7%、90.0%	43.0%、91.3%
HER2-High BC ORR	75.0%	54.5%
HER2-Low BC ORR	40.0%	16.7%

Notes: 1. COD: October 26, 2023, The median follow-up time is 4.2 months, with a median administration cycle of 5 cycles (1-18 cycles), and the longest administration time exceeding 1 year; 2. The median follow-up time is 6.7 months; 3. BC: breast cancer, GC: gastric cancer, OC: ovarian cancer, UC: urinary tract cancer, EC: esophageal cancer, LC: lung cancer



KN046 Dual blockade of PD-L1 and CTLA-4 - PD-(L)1 refractory solid tumor - PD-(L)1 Inadequate response - Positioning the first line and perioperative period - Nositioning the first line and perioperative period







ENWEIDA(KN035): Conducting Multiple Clinical Trials

IND

31



Proof of concept

Pivotal

NDA

• The company revenue from ENWEIDA[®] is RMB196 million in 2023

Combo/

Mono

Indication

- In November 2023, KN035 in combination with lenvatinib was granted breakthrough therapy designation for the treatment of non-MSI-H¹/non-dMMR² advanced endometrial cancer that has failed or intolerant of at least one prior line of platinumbased chemotherapy.
- In January 2024, we entered into a license agreement with Glenmark to develop and commercialize the oncology indications of KN035 in India, Asia Pacific (except Singapore, Thailand and Malaysia), Middle East and Africa, Russia, Commonwealth of Independent States and Latin America.





Thank you!

Q&A